Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$1.62 USD
-0.06 (-3.57%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $1.64 +0.02 (1.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AUTL 1.62 -0.06(-3.57%)
Will AUTL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AUTL
AUTL's price falls by 2.33% on October 16, though its technical setup remains stable.
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush
Crossed Above 50 Day Moving Average appears for AUTL after 6.17% move
Needham Hosts Virtual Meeting Featuring AUTL on October 22